A

Agenus
D

AGEN

2.83000
USD
0.07
(2.54%)
مغلق
حجم التداول
0
الربح لكل سهم
-8
العائد الربحي
-
P/E
-0
حجم السوق
66,821,768
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRVS
    -0.08000
    (-1.57%)
    5.01000 USD
    F
    FATE
    0.04000
    (2.42%)
    1.69000 USD
    G
    GNFT
    0.00000
    (0.00%)
    3.81000 USD
    O
    ONCY
    -0.05490
    (-6.10%)
    0.84510 USD
    P
    PRTA
    -0.810
    (-5.07%)
    15.180 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    V
    VYGR
    0.06000
    (1.05%)
    5.76000 USD
    المزيد
الأخبار

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).